- Home
- AKRO vs TARS Comparison
AKRO vs TARS Comparison
Compare AKRO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- TARS
- Stock Information
- Founded
- AKRO 2017
- TARS 2016
- Country
- AKRO United States
- TARS United States
- Employees
- AKRO N/A
- TARS N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- TARS Medicinal Chemicals and Botanical Products
- Sector
- AKRO Health Care
- TARS Health Care
- Exchange
- AKRO Nasdaq
- TARS Nasdaq
- Market Cap
- AKRO 2.2B
- TARS 1.8B
- IPO Year
- AKRO 2019
- TARS 2020
- Fundamental
- Price
- AKRO $29.53
- TARS $54.35
- Analyst Decision
- AKRO Strong Buy
- TARS Strong Buy
- Analyst Count
- AKRO 8
- TARS 5
- Target Price
- AKRO $46.83
- TARS $54.20
- AVG Volume (30 Days)
- AKRO 535.2K
- TARS 469.2K
- Earning Date
- AKRO 11-08-2024
- TARS 11-13-2024
- Dividend Yield
- AKRO N/A
- TARS N/A
- EPS Growth
- AKRO N/A
- TARS N/A
- EPS
- AKRO N/A
- TARS N/A
- Revenue
- AKRO N/A
- TARS $129,621,000.00
- Revenue This Year
- AKRO N/A
- TARS $895.24
- Revenue Next Year
- AKRO N/A
- TARS $73.78
- P/E Ratio
- AKRO N/A
- TARS N/A
- Revenue Growth
- AKRO N/A
- TARS 801.96
- 52 Week Low
- AKRO $15.32
- TARS $18.84
- 52 Week High
- AKRO $37.00
- TARS $54.44
- Technical
- Relative Strength Index (RSI)
- AKRO 46.87
- TARS 66.99
- Support Level
- AKRO $28.45
- TARS $51.08
- Resistance Level
- AKRO $31.41
- TARS $53.85
- Average True Range (ATR)
- AKRO 1.29
- TARS 2.41
- MACD
- AKRO -0.15
- TARS -0.05
- Stochastic Oscillator
- AKRO 37.64
- TARS 90.70
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.